Quantcast
Last updated on April 19, 2014 at 1:20 EDT

Latest Myocardial perfusion imaging Stories

2013-11-25 08:27:45

- Corus® CAD Gene Expression Test Impacts Clinical Decision-Making in Primary Care Practices and Reduces Unnecessary Referrals for Cardiac Testing in this Special Population - PALO ALTO, Calif., Nov. 25, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced results from a multi-center, real-world registry study highlighting the clinical utility of Corus(®) CAD in evaluating suspected obstructive coronary artery...

2013-11-18 12:30:17

- Data Presented Demonstrate the Advantages of Corus® CAD in Improving Clinical Decision-Making and Reducing Diagnostic Test Overutilization in Women with Symptoms Suggestive of Obstructive Coronary Artery Disease - PALO ALTO, Calif., Nov. 18, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results from two studies reinforcing the value of Corus(®) CAD as an initial diagnostic test for the evaluation of...

2013-10-29 12:01:23

Among patients with early stages of breast cancer, those whose hearts were more directly irradiated with radiation treatments on the left side in a facing-up position had higher risk of heart disease, according to research letter by David J. Brenner, Ph.D, D.Sc, of Columbia University Medical Center, New York, and colleagues. Several reports have suggested links between breast cancer radiation and long-term cardiovascular-related deaths, according to the study background. Researchers...

2013-10-21 08:29:25

- Corus® CAD is Effective in Excluding the Diagnosis of Obstructive Coronary Artery Disease in the Primary Care Setting and Helps Reduce Unnecessary Healthcare Expense - PALO ALTO, Calif., Oct. 21, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of a multi-center, real-world registry study demonstrating the clinical utility of Corus® CAD, a blood-based gene expression test, in the evaluation of...

2013-10-10 08:29:32

- Corus® CAD Has Potential to Reduce Cardiac Diagnostic Costs in Women by More Than $500 per Patient - PALO ALTO, Calif., Oct. 10, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of two studies indicating that Corus(®) CAD, a blood-based gene expression test, may help reduce unnecessary cardiac testing and costs by aiding clinician decision-making in the evaluation of women with symptoms...

2013-09-03 08:28:48

Corus CAD Gene Expression Test Helped Cardiologists Determine Which Patients with Symptoms Suggestive of Obstructive Coronary Artery Disease (CAD) Did Not Require Further Cardiac Testing PALO ALTO, Calif., Sept. 3, 2013 /PRNewswire/ -- CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of results from the Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern...

2013-07-18 08:29:50

- Two Studies to be Presented at "What a Difference an X Makes: The State of Women's Health Research" Validate the Accuracy and Clinical Utility of Corus® CAD, the Only Sex-Specific Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., July 18, 2013 /PRNewswire/ -- CardioDx, Inc., a leader in the field of cardiovascular genomic diagnostics, today announced that the company will present two studies demonstrating the accuracy and clinical utility of...

2013-06-11 14:06:05

Molecular imaging technique detects arterial disease in the heart earlier and in finer detail than other leading imaging methods Coronary artery disease (CAD) is one of the world´s most prevalent and silent killers. Positron emission tomography (PET), which images miniscule abnormalities in cellular metabolism, can tip off clinicians about cardiac disasters waiting to happen– including sudden death from a heart attack–better than standard angiography, researchers revealed...

2013-05-30 08:29:57

PALO ALTO, Calif., May 30, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced that the company will present at the Jefferies 2013 Global Healthcare Conference, taking place June 3-6, 2013 in New York, NY. David Levison, the company's President and Chief Executive Officer, will provide an overview of CardioDx and Corus(®) CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD) on...

2013-05-20 08:27:53

- Use of Corus® CAD Led to a Statistically Significant Reduction in Additional Cardiac Testing - PALO ALTO, Calif., May 20, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced the publication of the IMPACT-CARD (Investigation of a Molecular Personalized Coronary Gene Expression Test on Cardiology Practice Pattern) trial in Critical Pathways in Cardiology. This prospective study conducted at Vanderbilt University...